Seeking Alpha

Endologix (ELGX +1.8%) pipeline looks impressive, says Oppenheimer. After meeting with...

Endologix (ELGX +1.8%) pipeline looks impressive, says Oppenheimer. After meeting with management, the firm says ELGX's growth story remains intact and that abdominal aortic aneurysm market volumes and pricing remain solid. The firm thinks the Street is still underestimating the value of the company's Nelix treatment and reiterates a Buy on the stock.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector